Since the March Newsletter was released, there have been a few developments with the Desert of the Real Quantum Multiplier Portfolio. LOXO, IDSK, XPO and IDCC hit their stop loss points. Gains were booked on all but IDCC. Details of these transactions are set out below.
But the Authors hit a Ground-Rule Double with Clovis Technology, Inc. (CLVS). Clovis Technology is a biotech company that has cancer products called Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucarparib is approved for breast cancer treatment and is showing promise for the treatment of ovarian cancer. Julie, as a molecular biologist, is watching the development of these drugs and the company.
CLVS is currently one of the talks of the market with mostly bullish projections. The Authors' methodology does not consider such transitory stock market "noise," but does consider the recommendations of well-established analysts. But we are always primarily guided by the core principles of the Desert of the Real Economics and Investment Analysis Methodology.
CLVS was added to the portfolio on March 2, and has been held for 14 days. It was purchased for $60.62 and on March 16th is trading at $74.35, a 23% in two weeks, a whopping 590% annualized return. The stop loss is in a $68.
Closed Positions:
LOXO
|
2/6/17
|
2/14/17
|
$49.60
|
$65.93
|
32.92%
|
8
|
1502.13%
|
XPO
|
2/15/17
|
3/16/17
|
$49.00
|
50.43
|
2.92%
|
29
|
42.28%
|
IDCC
|
2/1/17
|
2/23/17
|
$99.95
|
$95.05
|
-4.90%
|
ADSK
|
2/10/17
|
3/16/17
|
$83.50
|
$85.50
|
2.40%
|
No comments:
Post a Comment